Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Boston Scientific extends cash tender offer for EndoChoice

Boston Scientific announced that its wholly owned merger subsidiary, Falcon Merger Corp., has extended its previously announced tender offer for all shares of EndoChoice Holdings (GI) at a price of $8.00 per share net to the holder in cash.

Boston Scientific has extended the expiration of the Offer until one minute following 11:59 p.m., New York City time, on November 21, 2016, unless further extended in accordance with the Merger Agreement.

The Offer, which was previously scheduled to expire one minute following 11:59 p.m., New York City time, on November 4, 2016, was extended to allow additional time for the satisfaction of the conditions of the Offer set forth in the Merger Agreement (as defined in the Offer to Purchase).

The Depositary has advised Boston Scientific that, as of the close of business, New York City time on November 3, 2016, approximately 17,332,100 Shares have been validly tendered and not properly withdrawn pursuant to the Offer, representing approximately 66.5% of the Shares outstanding, determined on a fully diluted basis, as defined in the Merger Agreement.

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.

As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.

Based near Atlanta, Georgia, EndoChoice is a medical technology company focused on the manufacturing and commercialization of platform technologies including endoscopic imaging systems, devices and infection control products and pathology services for specialists treating a wide range of gastrointestinal conditions, including colon cancer.

EndoChoice serves more than 2,500 customers in the United States and works with distribution partners in 30 countries. EndoChoice was founded in 2008 and has rapidly developed a broad and innovative product portfolio. EndoChoice and Full Spectrum Endoscopy (Fuse®) are registered trademarks of EndoChoice Holdings, Inc.